Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Epigenetic treatment-mediated modulation of PD-L1 predicts potential therapy resistance over response markers in myeloid malignancies: A molecular mechanism involving effectors of PD-L1 reverse signaling.

Liu H, Hu Y, Rimoldi R, Von Hagt C, Khong EWC, Lee N, Flemming S, Spencer A, Dear AE.

Oncol Lett. 2019 Feb;17(2):2543-2550. doi: 10.3892/ol.2018.9841. Epub 2018 Dec 17.

2.

Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis.

Gaspari T, Spizzo I, Liu H, Hu Y, Simpson RW, Widdop RE, Dear AE.

Diab Vasc Dis Res. 2018 Jan;15(1):64-73. doi: 10.1177/1479164117733626. Epub 2017 Oct 4. Erratum in: Diab Vasc Dis Res. 2018 Jul;15(4):364.

PMID:
28976221
3.

Epigenetic regulation of miRNA-124 and multiple downstream targets is associated with treatment response in myeloid malignancies.

Liu H, Pattie P, Chandrasekara S, Spencer A, Dear AE.

Oncol Lett. 2016 Sep;12(3):2175-2180. Epub 2016 Jul 25.

4.

Epigenetic Modulators and the New Immunotherapies.

Dear AE.

N Engl J Med. 2016 Feb 18;374(7):684-6. doi: 10.1056/NEJMcibr1514673. No abstract available.

PMID:
26886527
5.

Erratum to: 'TElmisartan in the management of abDominal aortic aneurYsm (TEDY): The study protocol for a randomized controlled trial'.

Morris DR, Cunningham MA, Ahimastos AA, Kingwell BA, Pappas E, Bourke M, Reid CM, Stijnen T, Dalman RL, Aalami OO, Lindeman JH, Norman PE, Walker PJ, Fitridge R, Bourke B, Dear AE, Pinchbeck J, Jaeggi R, Golledge J.

Trials. 2016 Jan 20;17:43. doi: 10.1186/s13063-016-1183-x. No abstract available.

6.

Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis.

Gaspari T, Brdar M, Lee HW, Spizzo I, Hu Y, Widdop RE, Simpson RW, Dear AE.

Diab Vasc Dis Res. 2016 Jan;13(1):56-68. doi: 10.1177/1479164115605000. Epub 2015 Sep 25.

PMID:
26408644
7.

TElmisartan in the management of abDominal aortic aneurYsm (TEDY): The study protocol for a randomized controlled trial.

Morris DR, Cunningham MA, Ahimastos AA, Kingwell BA, Pappas E, Bourke M, Reid CM, Stijnen T, Dalman RL, Aalami OO, Lindeman JH, Norman PE, Walker PJ, Fitridge R, Bourke B, Dear AE, Pinchbeck J, Jaeggi R, Golledge J.

Trials. 2015 Jun 17;16:274. doi: 10.1186/s13063-015-0793-z. Erratum in: Trials. 2016;17:43.

8.

Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.

Liu HB, Urbanavicius D, Tan P, Spencer A, Dear AE.

Int J Oncol. 2014 Oct;45(4):1742-8. doi: 10.3892/ijo.2014.2555. Epub 2014 Jul 22.

PMID:
25051119
9.

A novel agent with histone deacetylase inhibitory activity attenuates neointimal hyperplasia.

Rahmatzadeh M, Liu HB, Krishna SM, Gaspari TA, Welungoda I, Widdop RE, Dear AE.

Cardiovasc Drugs Ther. 2014 Oct;28(5):395-406. doi: 10.1007/s10557-014-6540-y.

PMID:
25005755
10.

Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells.

Wightman F, Lu HK, Solomon AE, Saleh S, Harman AN, Cunningham AL, Gray L, Churchill M, Cameron PU, Dear AE, Lewin SR.

AIDS. 2013 Nov 28;27(18):2853-62. doi: 10.1097/QAD.0000000000000067.

11.

Exenatide in acute ischemic stroke.

Daly SC, Chemmanam T, Loh PS, Gilligan A, Dear AE, Simpson RW, Bladin CF.

Int J Stroke. 2013 Oct;8(7):E44. doi: 10.1111/ijs.12073. No abstract available.

PMID:
24024920
13.

The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model.

Gaspari T, Welungoda I, Widdop RE, Simpson RW, Dear AE.

Diab Vasc Dis Res. 2013 Jul;10(4):353-60. doi: 10.1177/1479164113481817. Epub 2013 May 14.

PMID:
23673376
14.

GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells.

Hu Y, Liu H, Simpson RW, Dear AE.

Mol Biol Rep. 2013 Mar;40(3):2273-9. doi: 10.1007/s11033-012-2290-8. Epub 2012 Nov 28. Erratum in: Mol Biol Rep. 2013 Feb;40(2):2059. Y, Hu [corrected to Hu, Yunshan]; Hb, Liu [corrected to Liu, HongBin]; Rw, Simpson [corrected to Simpson, Richard W]; Ae, Dear [corrected to Dear, Anthony E].

PMID:
23187735
15.

Derivation of endothelial cells from human embryonic stem cells in fully defined medium enables identification of lysophosphatidic acid and platelet activating factor as regulators of eNOS localization.

Costa M, Sourris K, Lim SM, Yu QC, Hirst CE, Parkington HC, Jokubaitis VJ, Dear AE, Liu HB, Micallef SJ, Koutsis K, Elefanty AG, Stanley EG.

Stem Cell Res. 2013 Jan;10(1):103-17. doi: 10.1016/j.scr.2012.10.003. Epub 2012 Oct 22.

16.

Clinical-scientific notes.

Dick RJ, Byron KA, Dear AE.

Intern Med J. 2012 Oct;42 Suppl 5:7-8. doi: 10.1111/j.1445-5994.2012.02896.x. No abstract available.

PMID:
23035675
17.

A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model.

Gaspari T, Liu H, Welungoda I, Hu Y, Widdop RE, Knudsen LB, Simpson RW, Dear AE.

Diab Vasc Dis Res. 2011 Apr;8(2):117-24. doi: 10.1177/1479164111404257. Erratum in: Diab Vasc Dis Res. 2012 Jan;9(1):79.

PMID:
21562063
18.

The anti-leukemic effect and molecular mechanisms of novel hydroxamate and benzamide histone deacetylase inhibitors with 5-aza-cytidine.

Liu HB, Mayes PA, Perlmutter P, McKendrick JJ, Dear AE.

Int J Oncol. 2011 May;38(5):1421-5. doi: 10.3892/ijo.2011.914. Epub 2011 Jan 20.

PMID:
21253674
19.

Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis.

Dick RJ, Dear AE, Byron KA.

Heart Lung Circ. 2011 Oct;20(10):657-8. doi: 10.1016/j.hlc.2010.06.1054. Epub 2011 Jan 6.

PMID:
21215696
20.

PPARγ-independent thiazolidinedione-mediated inhibition of NUR77 expression in vascular endothelial cells.

Hu Y, Liu HB, Simpson RW, Dear AE.

J Endocrinol. 2011 Jan;208(1):R1-7. doi: 10.1677/JOE-10-0393. Epub 2010 Oct 26.

PMID:
20978184
21.

Genetic and epigenetic mechanisms and their possible role in abdominal aortic aneurysm.

Krishna SM, Dear AE, Norman PE, Golledge J.

Atherosclerosis. 2010 Sep;212(1):16-29. doi: 10.1016/j.atherosclerosis.2010.02.008. Epub 2010 Mar 6. Review.

PMID:
20347091
22.

The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells.

Shehu-Xhilaga M, Rhodes D, Wightman F, Liu HB, Solomon A, Saleh S, Dear AE, Cameron PU, Lewin SR.

AIDS. 2009 Sep 24;23(15):2047-50. doi: 10.1097/QAD.0b013e328330342c.

PMID:
19609198
23.

A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth.

Restall C, Doherty J, Liu HB, Genovese R, Paiman L, Byron KA, Anderson RL, Dear AE.

Int J Cancer. 2009 Jul 15;125(2):483-7. doi: 10.1002/ijc.24350.

24.
25.

A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules.

Liu H, Dear AE, Knudsen LB, Simpson RW.

J Endocrinol. 2009 Apr;201(1):59-66. doi: 10.1677/JOE-08-0468. Epub 2009 Jan 9.

PMID:
19136619
26.

Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin.

Newbold A, Lindemann RK, Cluse LA, Whitecross KF, Dear AE, Johnstone RW.

Mol Cancer Ther. 2008 May;7(5):1066-79. doi: 10.1158/1535-7163.MCT-07-2256. Erratum in: Mol Cancer Ther. 2014 Jun;13(6):1675.

27.

Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte-matrix interactions.

Golledge J, Karan M, Moran CS, Muller J, Clancy P, Dear AE, Norman PE.

Eur Heart J. 2008 Mar;29(5):665-72. doi: 10.1093/eurheartj/ehm557. Epub 2008 Feb 9.

PMID:
18263873
28.

Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasminogen [corrected] activator inhibitor-1 expression.

Liu H, Hu Y, Simpson RW, Dear AE.

J Endocrinol. 2008 Jan;196(1):57-65. doi: 10.1677/JOE-07-0387. Erratum in: J Endocrinol. 2010 Aug;206(2):248.

PMID:
18180317
29.

A novel histone deacetylase inhibitor reduces abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice.

Vinh A, Gaspari TA, Liu HB, Dousha LF, Widdop RE, Dear AE.

J Vasc Res. 2008;45(2):143-52. Epub 2007 Oct 24.

PMID:
17957103
30.

Genotype and adverse drug reactions to warfarin.

Byron KA, Dear AE.

Med J Aust. 2007 Jul 2;187(1):61-2. No abstract available.

PMID:
17605718
31.

Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.

Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L, Williams S, Wiegmans AP, Dear AE, Scott CL, Pellegrini M, Wei A, Richon VM, Marks PA, Lowe SW, Smyth MJ, Johnstone RW.

Proc Natl Acad Sci U S A. 2007 May 8;104(19):8071-6. Epub 2007 Apr 30.

32.

Association between osteopontin and human abdominal aortic aneurysm.

Golledge J, Muller J, Shephard N, Clancy P, Smallwood L, Moran C, Dear AE, Palmer LJ, Norman PE.

Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):655-60. Epub 2006 Dec 14.

PMID:
17170369
33.

Conformational analogues of Oxamflatin as histone deacetylase inhibitors.

Dear AE, Liu HB, Mayes PA, Perlmutter P.

Org Biomol Chem. 2006 Oct 21;4(20):3778-84. Epub 2006 Aug 31.

PMID:
17024284
34.

Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation.

Liu HB, Hu YS, Medcalf RL, Simpson RW, Dear AE.

Biochem Biophys Res Commun. 2005 Aug 19;334(1):30-7.

PMID:
15990085
35.

Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis.

Dear AE, Gray F, Byron K.

Med J Aust. 2005 Apr 4;182(7):365-6; author reply 367-8. No abstract available.

PMID:
15954237
36.

Novel inhibitors of urokinase-type plasminogen activator and matrix metalloproteinase expression in metastatic cancer cell lines.

Cakarovski K, Leung JY, Restall C, Carin-Carlson A, Yang E, Perlmutter P, Anderson R, Medcalf R, Dear AE.

Int J Cancer. 2004 Jul 1;110(4):610-6.

37.

Novel mechanisms of apoptosis induced by histone deacetylase inhibitors.

Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA, Waterhouse NJ, Trapani JA, Johnstone RW.

Cancer Res. 2003 Aug 1;63(15):4460-71.

38.

Homocysteine: an aetiological contributor to peripheral vascular arterial disease.

Kuan YM, Dear AE, Grigg MJ.

ANZ J Surg. 2002 Sep;72(9):668-71. Review.

PMID:
12269921
40.

The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic molecule.

Dear AE, Medcalf RL.

Eur J Biochem. 1998 Mar 1;252(2):185-93. Review.

42.
43.

Supplemental Content

Loading ...
Support Center